Regen BioPharma is a biotech company focused on the immunology and immunotherapy space. It is engaged in the development of small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. In addition, the company offers products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy or radiotherapy treated cancer patients (HemaXellerate).